Performance of the ViroSeq HIV-1 genotyping system v2.0 on HIV-1 strains circulating in Senegal

Journal of Virological Methods

Volumn 188, Issue 1-2, 2013, Pages 97-103

  Thiam, Moussa ^a   Diop Ndiaye, Halimatou ^a   Kebe, Khady ^a   Vidal, Nicole ^c   Diakhate Lô, Rokhaya ^a   Diouara, Abou Abdallah Malick ^a   Leye, Nafissatou ^a   Ndiaye, Ousseynou ^a   Sow, Amina ^a   Ngom Gueye, Ndeye Fatou ^b   Mboup, Souleymane ^a   Toure Kane, Coumba ^a  

^a Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

^b Ambulatory Care Unit   (Senegal)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

Performance; Senegal; Sequencing primers; ViroSeq HIV 1 Genotyping System v2.0

Indexed keywords

EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SENEGAL; SEQUENCE ANALYSIS; VIRUS STRAIN;

ADULT; AGED; DNA PRIMERS; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MOLECULAR TYPING; SENEGAL; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84872254364     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2012.11.044     Document Type: Article

References (15)

1. Aghokeng A.F., Mpoudi-Ngole E., Chia J.E., Edoul E.M., Delaporte E., Peeters M. High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity. J. Clin. Microbiol. 2011, 49:1635-1641.
2. Chen J.H., Wong K.H., Chan K., Lam H.Y., Lee S.S., Li P., Lee M.P., Tsang D.N., Zheng B.J., Yuen K.Y., Yam W.C. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping. J. Clin. Virol. 2007, 39:125-131.
3. Cunningham S., Ank B., Lewis D., Lu W., Wantman M., Dileanis J.A., Jackson J.B., Palumbo P., Krogstad P., Eshleman S.H. Performance of the Applied Biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J. Clin. Microbiol. 2001, 39:1254-1257.
4. Diop-Ndiaye H., Toure-Kane C., Vidal N., Niama F.R., Niang-Diallo P.A., Dieye T., Gaye-Diallo A., Wade A.S., Peeters M., Mboup S. Surprisingly high prevalence of subtype C and specific HIV-1 subtype/CRF distribution in men having sex with men in Senegal. J. Acquir. Immune Def. Syndr. 2009, 52:249-252.
5. Diop-Ndiaye H., Toure-Kane C., Leye N., Ngom-Gueye N.F., Montavon C., Peeters M., Mboup S. Antiretroviral drug resistance mutations in antiretroviral-naive patients from Senegal. AIDS Res. Hum. Retroviruses 2010, 26:1133-1138.
6. Eshleman S.H., Hackett J.J., Swanson P., Cunningham S.P., Drews B., Brennan C., Devare S.G., Zekeng L., Kaptué L., Marlowe N. Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J. Clin. Microbiol. 2004, 42:2711-2717.
7. Eshleman S.H., Crutcher G., Petrauskene O., Kunstman K., Cunningham S.P., Trevino C., Davis C., Kennedy J., Fairman J., Foley B., Kop J. Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer. J. Clin. Microbiol. 2005, 43:813-817.
8. Hamel D.J., Sankalé J.L., Eisen G., Meloni S.T., Mullins C., Gueye-Ndiaye A., Mboup S., Kanki P.J. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV-1 diversity. AIDS Res. Hum. Retroviruses 2007, 23:1189-1196.
9. Huang D.D., Eshleman S.H., Brambilla D.J., Palumbo P.E., Bremer J.W. Evaluation of the editing process in human immunodeficiency virus type 1 genotyping. J. Clin. Microbiol. 2003, 41:3265-3272.
10. Maes B., Schrooten Y., Snoeck J., Derdelinckx I., Van Ranst M., Vandamme A.M., Van Laethem K. Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory. J. Virol. Methods 2004, 119:45-49.
11. Mracna M., Becker-Pergola G., Dileanis J., Guay L.A., Cunningham S., Jackson J.B., Eshleman S.H. Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda. J. Clin. Microbiol. 2001, 39:4323-4327.
12. Peeters M., Aghokeng A.F., Delaporte E. Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clin. Microbiol. Infect. 2010, 16:1525-1531.
13. Tee K.K., Li X.J., Nohtomi K., Ng K.P., Kamarulzaman A., Takebe Y. Identification of a novel circulating recombinant form (CRF33_01B) disseminating widely among various risk populations in Kuala Lumpur, Malaysia. J. Acquir. Immune Def. Syndr. 2006, 43:523-529.
14. Toure-Kane C., Montavon C., Faye M.A., Gueye P.M., Sow P.S., Ndoye I., Gaye-Diallo A., Delaporte E., Peeters M., Mboup S. Identification of all HIV type 1 group M subtypes in Senegal a country with low and stable seroprevalence. AIDS Res. Hum. Retroviruses 2000, 16:603-609.
15. Tournoud M., Etard J.F., Ecochard R., DeGruttola V. Adherence to antiretroviral therapy virological response, and time to resistance in the Dakar cohort. Stat. Med. 2010, 29:14-32.